HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Partridge, E. E. Articles by Barnes, M. N. Search for Related Content PubMed PubMed Citation Articles by Partridge, E. E. Articles by Barnes, M. N.

CA: A Cancer Journal for Clinicians, Vol 49, Issue 5 297-320, Copyright © 1999 by American Cancer Society

ARTICLES

Epithelial ovarian cancer: prevention, diagnosis, and treatment

E. E. Partridge and M. N. Barnes
Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham, AL, USA.

The leading cause of death from gynecologic malignancies in the United States is epithelial ovarian cancer. The significant risk factor for development of ovarian cancer is advancing age, although there is clearly a genetic predisposition--often associated with the BRCA1 and BRCA2 genes--in at least 5% to 10% of all epithelial ovarian cancers. Oral contraceptives are known to reduce the risk for development of ovarian cancer and should be considered as a method of birth control in women at increased risk. Currently, there is no acceptable method of screening for this disease, although measurement of CA-125 level and transvaginal ultrasound have been utilized. Ovarian cancer is a surgically staged disease. In apparent early-stage disease, complete surgical staging is critical for the selection of adjunctive therapy. In advanced-stage disease, the goal is primary cytoreduction. Standard postoperative therapy for advanced-stage ovarian cancer includes platinum-based chemotherapy with the substitution of paclitaxel for cyclophosphamide occurring in the last decade. Despite these advances in chemotherapy, ovarian cancer continues to be fatal in far too many cases.

This article has been cited by other articles:

				J. M. Saucier, J. Yu, A. Gaikwad, R. L. Coleman, J. K. Wolf, and J. A. Smith Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model Journal of Oncology Pharmacy Practice, March 1, 2007; 13(1): 39 - 45. [Abstract] [PDF]

				L. Y. Han, C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, T.-J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, et al. Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Res., September 1, 2006; 66(17): 8633 - 8639. [Abstract] [Full Text] [PDF]

				J. S. de Moor, C. A. de Moor, K. Basen-Engquist, A. Kudelka, M. W. Bevers, and L. Cohen Optimism, Distress, Health-Related Quality of Life, and Change in Cancer Antigen 125 Among Patients With Ovarian Cancer Undergoing Chemotherapy Psychosom Med, July 1, 2006; 68(4): 555 - 562. [Abstract] [Full Text] [PDF]

				D. Lane, M. Cote, R. Grondin, M.-C. Couture, and A. Piche Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol. Cancer Ther., March 1, 2006; 5(3): 509 - 521. [Abstract] [Full Text] [PDF]

				A. Koushik, D. J. Hunter, D. Spiegelman, K. E. Anderson, A. A. Arslan, W. L. Beeson, P. A. van den Brandt, J. E. Buring, J. R. Cerhan, G. A. Colditz, et al. Fruits and Vegetables and Ovarian Cancer Risk in a Pooled Analysis of 12 Cohort Studies Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2160 - 2167. [Abstract] [Full Text] [PDF]

				A. Okamoto, T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, et al. Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells Clin. Cancer Res., August 15, 2005; 11(16): 6030 - 6039. [Abstract] [Full Text] [PDF]

				J.-H. Kim, D. Herlyn, K.-k. Wong, D.-C. Park, J. O. Schorge, K. H. Lu, S. J. Skates, D. W. Cramer, R. S. Berkowitz, and S. C. Mok Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4782 - 4791. [Abstract] [Full Text] [PDF]

				M. Navo and J. A. Smith Update on the Prevention and Treatment of Ovarian Cancer Journal of Pharmacy Practice, June 1, 2003; 16(3): 149 - 156. [Abstract] [PDF]

				M. N. Barnes, W. E. Grizzle, C. J. Grubbs, and E. E. Partridge Paradigms for Primary Prevention of Ovarian Carcinoma CA Cancer J Clin, July 1, 2002; 52(4): 216 - 225. [Abstract] [Full Text] [PDF]

				F. J. Kelly, C. R. Miller, D. J. Buchsbaum, J. Gomez-Navarro, M. N. Barnes, R. D. Alvarez, and D. T. Curiel Selectivity of TAG-72-targeted Adenovirus Gene Transfer to Primary Ovarian Carcinoma Cells versus Autologous Mesothelial Cells in Vitro Clin. Cancer Res., November 1, 2000; 6(11): 4323 - 4333. [Abstract] [Full Text] [PDF]